December 6th 2024
Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.
Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.
November 23rd 2024
The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.
The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.
November 22nd 2024
Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France.
Astellas and Sony Enter ADC Platform Collaboration
Astellas and Sony will collaborate to discover a novel ADC platform for use in oncology.
FTC Sues to Block Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics
In a brief, the Federal Trade Commission cited concerns about the acquisition resulting in an increased monopoly on Amgen’s newly acquired thyroid eye disease and chronic refractory gout treatments.
BiOneCure Therapeutics and Nanjing Leads Biolabs Partner to Develop ADCs for Solid Tumors
Under the collaboration, BiOneCure Therapeutics and Nanjing Leads Biolabs intend to develop a range of innovative antibody-drug conjugates for treating solid tumors.
Amgen and Tscan Therapeutics Team Up to Identify Novel Targets in Crohn's Disease
In a deal potentially worth more than $530 million, Amgen will use TScan Therapeutics’ target discovery platform to home in on novel targets for Crohn’s disease treatment.
Sandoz and Just – Evotec Biologics Form Biosimilars Pact
The new partnership between Sandoz, a Novartis division, and Just – Evotec Biologics will aim to develop and manufacture multiple biosimilars.
Baxter Divests BioPharma Solutions Department in $4.25 Billion Deal
Private investors from Advent International and Warburg Pincus will operate the assets as an independent CDMO.
Ginkgo Bioworks and Boehringer Ingelheim Sign $405 Million Drug Discovery Deal
Boehringer Ingelheim will use Ginkgo’s metagenomic sequence database to identify potential lead molecules for diseases with high unmet patient needs.
Ramping Up Nucleic Acid Therapy Development
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
Young Pups and Leopards
The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.
Aspect Biosystems, Novo Nordisk Partner to Develop Bioprinted Tissue Therapeutics
Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics.
EHA Data Leak Shows Positive J&J Cancer Treatment Findings
The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.
Indian Pharma Companies Poised for Surge?
A report from Business Standard highlighted India’s recent growth in the pharma sector.
GSK and BELLUS Health Enter Acquisition Agreement
GSK has reached an agreement to acquire late-stage biopharmaceutical company BELLUS Health.
Merck to Purchase Prometheus Biosciences for $10.8 Billion
Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.
Caribou Biosciences Gets FDA Granted Fast Track Designation for Allogeneic CAR-T Cell Therapy
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
Novo Nordisk and Aspect Biosystems Enter Strategic Partnership
Under this partnership, the two companies will develop bioprinted tissue therapeutics for diabetes and obesity.
Ginkgo Bioworks Acquires AAV Capsid Technology and Forms Partnership for Next-Gen CAR-T Cell Therapies
Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.
AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.
FDA Regulatory Authority Under Attack
Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?
J&J Proposes $8.9 Billion Payment in Talc Powder Litigation
If approved, Johnson & Johnson would pay $8.9 billion to resolve all current and future claims in its ongoing talc litigation.
Sartorius to Acquire Polyplus in $2.6 Billion Deal
Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.
A New Hope for Children Living with HIV
New child-friendly treatment options and initiatives are improving the outlook of children living with HIV in Europe.
Zauberkugel: Pfizer’s Seagen Acquisition
What can we take away from Pfifzer's acquisition of Seagen?
Who’s Got Game?
Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.
Exothera Partners with Remedium to Scale-Up Manufacturing of Gene Therapy Drug Candidate
CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.
Takeda to Invest ¥100 Billion (US$754 Million) into New Plasma Therapy Manufacturing Facility
Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.
US Supreme Court Weighs Biologics Patents in Amgen vs. Sanofi Case
The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.
Illuminating the State of Outsourcing with Stephen Houldsworth (DCAT 2023)
Stephen Houldsworth, VP and Head of Platform Management & Marketing at CordenPharma, dives into ongoing trends in the outsourcing space.
Ingredion Announces Strategic Investments in India Expanding into High-Value Pharmaceutical Ingredients
Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.
Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement
Harm Reduction Therapeutics and Catalent have signed a commercial supply agreement for naloxone nasal spray to reverse opioid overdoses.